Revolution Medicines, Inc.

Corporate structure

Significant subsidiaries, as filed

From Exhibit 21 of this company’s most recent annual report. The SEC requires only significant subsidiaries to be listed, so this is not a complete corporate family — it is exactly what Revolution Medicines, Inc. filed.

Source: Exhibit 21, as filed with the SEC · accession 0001193125-26-071563

Reported financials

As filed with the SEC

Annual figures from this company’s own 10-K filings, tagged in XBRL. Restatements are reflected — where a year was refiled, the most recent value is shown.

Corporate actions

Stock splits

As reported in this company’s SEC filings. A ratio below 1 is a reverse split.

Legal proceedings

As disclosed in the annual report

Item 3 of Revolution Medicines, Inc.’s Form 10-K for fiscal 2025, filed 2026-02-25. This is the company’s own statement about its material legal proceedings — not a court record, and not a search of any docket.

From time to time, we are and may become involved in litigation or other legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

On December 9, 2024, Nemeth v. Casdin, et al., Case No. 2024-1268-KSJM (Del. Ch.), was filed in the Court of Chancery of the State of Delaware (the Complaint) arising from CM Life Sciences III., Inc.’s (CMLS III) December 17, 2021 merger with EQRx, Inc. (Legacy EQRx) (the Merger). The Complaint was filed by former stockholders of CMLS III and brings claims for breach of fiduciary duty and unjust enrichment against members of CMLS III’s board of directors, CMLS III’s officers, and CMLS III’s sponsor in connection with the Merger. The Complaint also brings claims for aiding and abetting breaches of fiduciary duties against certain investment firms involved with the merger process, the Company, solely as successor-in-interest to EQRx, and Legacy EQRx’s former Executive Chairman and CEO, Alexis Borisy, who is also on the Company’s board of directors. Defendants moved to dismiss the Complaint in February 2025. The parties reached an agreement to resolve the matter, which was filed with the court on January 6, 2026, and remains subject to court approval. We have recorded an accrual of $5.0 million in accrued and other current liabilities as of December 31, 2025, based on its expected contribution under the agreement and anticipated insurance recoveries.

Quoted from the filing as submitted to the SEC. Read Item 3 in the 10-K itself ↗

Filing activity

What Revolution Medicines, Inc. files

Form types across the 848 filings in SEC EDGAR’s current filing index for this company, 2016-12-21 to 2026-09-18.

Filing history

The 25 most recent filings

Of 848 in EDGAR’s current filing index for this company. Every filing, including older ones, is in the SEC’s own index ↗ .

Continue searching

← Back to EIN lookup